Diabetic nephropathy is a frequent microvascular complication that occurs in approximately
40% of patients with either type 1 or type 2 diabetes. The most common cause of end-stage
renal disease (ESRD) in the United States and in the developed world is diabetic nephropathy.
Currently, more than half the United States ESRD population has diabetes. More effective
therapies to prevent and treat diabetic nephropathy are urgently needed. One way to increase
therapeutic effectiveness is to refine treatment targets based on improved understanding of
how treatments modulate disease processes. The purpose of this study is to determine whether
a treatment for diabetic nephropathy, the angiotensin receptor blocker candesartan, modifies
mediators of kidney injury independent of blood pressure and the relationships to drug dose.
Phase:
N/A
Details
Lead Sponsor:
Providence Health & Services
Collaborator:
AstraZeneca
Treatments:
Angiotensin II Angiotensinogen Candesartan Candesartan cilexetil